Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA ‐A24‐positive pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA ‐A24‐positive pancreatic adenocarcinoma

Published:2019-07-23 Issue:8 Volume:110 Page:2378-2385
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Shima Hiroaki¹,Tsurita Giichiro²,Wada Satoshi³⁴,Hirohashi Yoshihiko⁵^ORCID,Yasui Hiroshi⁶,Hayashi Hiroshi⁷,Miyakoshi Takashi⁷,Watanabe Kazue⁵,Murai Aiko⁵,Asanuma Hiroko⁸,Tokita Serina⁵,Kubo Terufumi⁵,Nakatsugawa Munehide⁵,Kanaseki Takayuki⁵,Tsukahara Tomohide⁵^ORCID,Nakae Yutaka⁹,Sugita Osamu⁷,Ito Yoichi M.¹⁰,Ota Yasunori¹¹,Kimura Yasutoshi¹,Kutomi Goro¹,Hirata Koichi¹,Mizuguchi Toru¹,Imai Kohzoh⁶,Takemasa Ichiro¹,Sato Noriyuki⁵,Torigoe Toshihiko⁵

Affiliation:

1. Department of Surgery, Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan

2. Department of Surgery Research Hospital, The Institute of Medical Science The University of Tokyo Tokyo Japan

3. Department of Clinical Diagnostic Oncology Showa University Tokyo Japan

4. Cancer Vaccine Center Kanagawa Cancer Center Kanagawa Japan

5. Department of Pathology Sapporo Medical University School of Medicine Sapporo Japan

6. The Institute of Medical Science The University of Tokyo Tokyo Japan

7. Hokkaido University Hospital Clinical Research and Medical Innovation Center Sapporo Japan

8. Department of Surgical Pathology Sapporo Medical University School of Medicine Sapporo Japan

9. Collaboration Center for Community and Industry Sapporo Medical University School of Medicine Sapporo Japan

10. Department of Biostatistics Hokkaido University Graduate School of Medicine Sapporo Japan

11. Department of Pathology Research Hospital, The Institute of Medical Science The University of Tokyo Tokyo Japan

Funder

Japan Agency for Medical Research and Development

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14106

Reference17 articles.

1. Cancer statistics, 2017

2. Cancer immunotherapy using checkpoint blockade

3. Validating survivin as a cancer therapeutic target

4. An HLA‐A24‐restricted cytotoxic T lymphocyte epitope of a tumor‐associated protein, survivin;Hirohashi Y;Clin Cancer Res,2002

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions;Current Oncology;2024-09-04

2. In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens;Frontiers in Immunology;2024-08-08

3. The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review;Journal of Gastrointestinal Cancer;2024-07-08

4. Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application;Frontiers in Immunology;2024-05-02

5. Clinical immunotherapy in pancreatic cancer;Cancer Immunology, Immunotherapy;2024-03-02